AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 5.3 |
Market Cap | 270.49M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.47 |
PE Ratio (ttm) | -4.66 |
Forward PE | n/a |
Analyst | Buy |
Ask | 10.87 |
Volume | 226,873 |
Avg. Volume (20D) | 231,109 |
Open | 7.09 |
Previous Close | 7.05 |
Day's Range | 6.80 - 7.27 |
52-Week Range | 5.46 - 14.84 |
Beta | undefined |
About LUNG
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence...
Analyst Forecast
According to 6 analyst ratings, the average rating for LUNG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 75.18% from the latest price.
Next Earnings Release
Analysts project revenue of $22.29M, reflecting a 15.62% YoY growth and earnings per share of -0.45, making a 25.00% increase YoY.